The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics).
Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in Berlin
2021-04-14 / Eckert & Ziegler is proud to announce that it is expanding its production site in Berlin, Germany, with a new production facility for the contract manufacturing of radiopharmaceuticals.more ...
Eckert & Ziegler Receives Technetium Generator Licenses for Brazil
The Brazilian regulator ANVISA has provided Eckert & Ziegler Brasil Comercial Ltda., a fully owned subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), with a li...more ...
Eckert & Ziegler: Dividend Proposal EUR 0.45 per Share. Profit Increase in 2020. Positive Outlook for 2021.
Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 176.1 million (previous year EUR 178.5 million) and a net profit of EUR 22.9 million (previous year EUR 22.0 million) in the 2020 ...more ...
Epigenetik und die große Frage: Beeinflusst die Umwelt unser Erbgut?
Die Epigenetik bietet konzeptionell neue Ansätze für das Verständnis genetischer Regulation von Entwicklungs- und Erkrankungs-Prozessen.more ...
GMP Biotech Summer School
Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)more ...
Pharmacokinetics - Essentials for Project Managers in Biotech Companies
Basics in understanding pharmacokinetics in clinicial development - for non-physiciansmore ...